TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
ENTX

Entera Bio Ltd

Healthcare · Biotechnology

3.10$ -3.4% vs. previous close Closing price · As of: Nov 13, 2026

Ownership

Ownership Structure

Who owns Entera Bio Ltd (ENTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 67.6% of the shares are freely tradable; institutional investors hold 34.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 34.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 6.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 67.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 174Mio.

Largest Shareholders

Institutions

Institutions ENTX
Name Stake (%) Shares Change (%) Date
Knoll Capital Management LP 3.38 5,881,879 +0.0 06/30/2026
Bvf Inc 1.40 2,425,000 +0.0 06/30/2026
Siren, L.L.C. 0.42 736,457 +0.0 06/30/2026
Renaissance Technologies Corp 0.21 368,847 -22.1 06/30/2026
Parkman Healthcare Partners LLC 0.16 274,497 -4.9 06/30/2026
PNC Financial Services Group Inc 0.16 273,031 +2,630.3 06/30/2026
Seven Fleet Capital Management LP 0.11 191,354 -6.9 06/30/2026
HighTower Advisors, LLC 0.04 74,573 +102.5 06/30/2026

Funds

Funds ENTX
Name Stake (%) Shares Change (%) Date
Fidelity Nasdaq Composite Index 0.10 178,259 +496.0 08/31/2026
WEALTHGATE Biotech Fund Inst 0.07 116,394 +52.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?